MRNA Stock Up Over 7%, Moderna Announces 2-in-1 Covid Vaccine Shot
Coinspeaker
MRNA Stock Up Over 7%, Moderna Announces 2-in-1 Covid Vaccine Shot
Moderna Inc (NASDAQ: MRNA) stock closed trading on Thursday at $455.92, up 7.81%. Yesterday’s close increased the odds of Moderna stock revisiting ATH in the next few weeks or days. The sudden spike has been attributed to news that the company is developing a two-in-one COVID-19 vaccine. According to Moderna, the combined vaccine shot will include a vaccine against flu.
Today, we shared positive pre-clinical data demonstrating our ability to combine 6 mRNAs against 3 different respiratory viruses in 1 vaccine: COVID-19 booster + Flu booster + RSV booster. #mRNA pic.twitter.com/6AEkhSJrO5
— Moderna (@moderna_tx) September 9, 2021
The company believes the mRNA field of study holds the key to humanity-based disease challenges. Notably, Moderna has been developing its mRNA-based vaccines for years but it will be live administering it to humans for the first time with the COVID-19 pandemic.
“Today we are announcing the first step in our novel respiratory vaccine program with the development of a single-dose vaccine that combines a booster against COVID-19 and a booster against flu. We are making progress on enrolling patients in our rare disease programs, and we are fully enrolled in our personalized cancer vaccine trial. We believe this is just the beginning of a new age of information-based medicines,” said Stéphane Bancel, Chief Executive Officer of Moderna.
Notably, Moderna’s Covid-19 vaccine, mRNA-1273, has been adopted by more than 50 countries and the World Health Organization (WHO) for emergency use by Adults. Additionally, the European Union and other jurisdictions have approved the use of Moderna’s vaccines to adolescents aged 12 and up.
Moderna Covid Vaccine Shot Update and the Global Condition
Notably, Moderna has submitted for a booster dose of mRNA-1273 at the 50 µg dose level for Emergency Use Authorization with the US FDA, Conditional Marketing Approval (CMA) with the European Medicines Agency (EMA) among other jurisdictions.
The quest to update the Covid-19 vaccine by Moderna follows the resurgence of the virus under a new variant dubbed Delta. Additionally, the quest falls in line with the Biden administration’s push to have everyone vaccinated fully in the United States.
In a press release, Joe Biden said that the government must increase vaccinations among the unvaccinated. “This is not about freedom or personal choice. it’s about protecting yourself and those around you,” he explained.
As the country averages about 150,000 new cases daily and 1,500 fatalities, Biden’s administration is keen to push for its federal employees to get vaccinated without a choice of testing. Additionally, a similar situation is taking place with big companies including Facebook Inc (NASDAQ: FB), Google LLC (NASDAQ: GOOGL), and Disney (NYSE: DIS).
Moderna stock has gained 668% and 336% in the past year and YTD respectively through Thursday according to MarketWatch.
MRNA Stock Up Over 7%, Moderna Announces 2-in-1 Covid Vaccine Shot